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Summary.-The effect of chemotherapy on natural killer (NK) activity and antibody-
dependent cell-mediated cytotoxicity (ADCC) in 15 advanced carcinomas of the lung
was examined with regard to the drug, dose, route and timing of administration.
The relationship between the effect of chemotherapy on the prognosis for the patients,
and the changes in NK activity and ADCC, was also analysed. The NK activity and
ADCC in patients with poor prognosis were significantly subnormal, even before
treatment. The NK activity and ADCC began to decrease 2 weeks after the initiation
of treatment and reached the lowest level during the 3rd or 4th week in all patients.
Thereafter, they returned to the pretreatment level in 8 patients with stabilized
disease. In contrast, they were not restored in 7 patients with progressive disease
and poor prognosis. In 4 patients it was found that the effect of chemotherapy with
pepleomycin and carbazilquinone on NK activity and ADCC differed according to the
drug used. From this pilot study it is suggested that NK activity and ADCC are
valuable prognostic factors in patients with advanced carcinoma of the lung, and
that detailed analysis of the effect of each anticancer agent on NK activity and ADCC
is desirable for the establishment of better treatment regimens for advanced carcin-
oma of the lung.
IN ADDITION to killer T cells and
macrophages, natural killer (NK) cells
and killer (K) cells are thought to play an
active role in the in vivo resistance to
tumour development and growth (Herber-
man & Holden, 1979; Habu et al., 1981).
There are two purposes in the clinical
measurement of NK activity and anti-
body-dependent cell-mediated cytotoxi-
city (ADCC) which is mediated by K
cells. One ofthem is to establish a relevant
and reproducible method by which host
modification through treatment can be
assessed (Hersh, 1 981). The other is to
develop a reliable monitoring procedure
for determining an effective treatment
protocol. The conventional nonspecific
imnmune responses such as skin reaction
to PPD, blastogenic response to phyto-
haemagglutinins, T- and B-cell subpopu-
lations, and T-cell subsets (Ty and T,u
cells) can be easily determined (Sone et al.,
1977), but the relationship between the
effect of treatment or the prognosis of
tumour-bearing patients and the changes
in these parameters has been relatively
obscure. It is of interest, therefore, to
ascertain whether there is any correlation
ofNK activity and ADCC with the clinical
course of cancer, and it is necessary to
know the NK activity and ADCC in tum-
our-bearing patients before the investiga-
tion of specific cytotoxicity for tumour-
associated antigens can proceed.
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According to our previous data, NK
activity is not decreased before chemo-
therapy in patients with Stage IIIMo or
IIIM1 carcinoma of the lung or with
metastatic pulmonary tumours. It is
decreased only in patients with poor
performance status, and is significantly
decreased after chemotherapy. ADCC also
shows a tendency to decrease in tumour-
bearing patients after chemotherapy
(Saijo et al., 1981, 1982a).
In this study, 15 previously untreated
patients with carcinoma of the lung
treated by chemotherapy alone were
examined for NK activity and ADCC
before treatment and weekly for 6 weeks
after treatment. The effect of anticancer
agents on NK activity and ADCC was
examined with regard to the drug, course,
route and timing of administration. The
relationship between the effect of treat-
ment and prognosis for the patients with
the changes in NK activity and ADCC
was also analysed.
MATERIALS AND METHODS
Patients.-Between November 1980 and
August 1981, 15 previously untreated patients
with a histologically proven diagnosis of
carcinoma of the lung received various
chemotherapeutic agents according to their
histology. Included are all T3 lesions regard-
less ofnodal status, and N2 lesions regardless
of T status, with (IIIM1-10 cases) or
without (IIIMo-5 cases) distant metastases.
They were classified by an Eastern Co-
operative Oncology Group (U.S.A.) per-
formance score (ECOG PS), which ranges
from 0 (healthy) to 4 (completely disabled).
The characteristics of each patient are listed
in Table 1. There were 4 squamous-cell
carcinomas, 7 adenocarcinomas, 1 large-cell
carcinoma and 3 small-cell carcinomas.
Treatment.-All the patients were random-
ly assigned to the chemotherapeutic regimens
listed in Table II. These regimens for carci-
noma of the lung were established according
to a modification of the uniform cancer
chemotherapy protocol used in national
hospitals in Japan. As shown in Table II,
all regimens were completed within 4 weeks
of the beginning of treatment. In 3 patients
with pleural effusion, an attempt was made
to drain as much of the effusion as possible
by tube drainage, and an anticancer agent,
mitomycin C (10 mg) or adriamycin (40 mg),
in 20-40 ml ofnormal saline was administered
i.p. once or twice weekly.
One patient (F.S.) was given Nocardia
rubra cell-wall skeleton (N-CWS, 500 jug)
once i.p. Except for one patient (Y.K.) who
TABLE I.-Characteristics ofpatients
Groups§ Name
A Y.K.
C.N.
T.N.
S.Y.
F.S.
S.S.
H.A.
M.S.
B T.K.
S.W.
S.N.
S.S.
T.F.
K.W.
Z.H.
Age
65
58
72
66
70
58
79
70
80
55
49
40
54
52
61
Sex
M
F
M
F
M
F
F
M
M
F
M
M
M
M
M
Histologyt PS*
Sq 2
Sq 2
Sq 0
Ad (W/D) 3
Ad (W/D) 2
Ad (P/D) 1
Ad (P/D) 1
Ad (P/D) 1
Sq
Ad (W/D)
Ad (W/D)
Large
Small (Intermediate)
Small (Oat)
Small (Oat)
1
1
1
1
4
4
TNM
T3NjMo
T2N2M1
T2N2Mo
T3N2M1
TgNoMo
T2NjMj
T2N2M1
T3N2Mo
T3NjMo
T3N2Ml
T2N2M1
T2N2Ml
T2N2M1
T3N2Ml
T2N2Ml
Stage
IIIMo
IIIM1
IIIMo
IIIM1
IIIMo
IIIM1
IIIM1
IIIMo
IIIMo
IIIM1
IIIM1
IIIM1
IIIM1
IIIM1
IIIM1
Pleural
effusion
+
Chemotherapy:
PLM+MMC
PLM+CQ
PLM+CQ
PLM+CQ
PLM+CQ
PLM+MMC
PLM+CQ
PLM+CQ
PLM+MMC
PLM+MMC
PLM+CQ
PLM+CQ
VCR+CPA +ACNU
VCR +ADM+ACNU
VCR +ADM+ACNU
* PS, performance status.
t Sq, squamous cell carcinoma; Ad,adenocarcinoma (W/D, well-differentiated; P/D, poorly differentiated).
Large, large-cell carcinoma; Small, small-cell carcinoma.
: PLM, pepleomycin (anticancer antibiotic); MMC, mitomycin C (anticancer antibiotic); CQ, caraba-
zilquinone (alkylating agent); VCR, vincristine (vinca alkaloid); CPA, cyclophosphamide (alkylating
agent); ACNU, nimustin (nitrosourea); ADM, Adriamycin (anticancer antibiotic).
§ A, disease stabilized by treatment; B, progressive disease.
13
181N. SAIJO ET AL.
TABLE II.-Chemotherapy regimens (see
last column ofTable I)
For small-cell carcinoma
VCR +ADM+ACNU
VCR (i.v.) 1-2 mg weekly x 4
ADM (i.v.) 0* 8 mg/kg (Days 3 and 4)
ACNU (i.v.) 3 mg/kg (Day 10)
VCR+CPA+ACNU
VCR (i.v.) 1 2 mg weekly x 4
CPA (i.v.) 20 mg/kg (Day 3)
ACNU (i.v.) 3 mg/kg (Day 10)
For other carcinomas
PLM+CQ
PLM 25- mg (i.m.) twice daily (Days 1-5, and
15-19)
CQ (i.v.) 0 12 mg/kg weekly x 3
or PLM 0
-4 mg/kg (i.v.) weekly x 4
CQ (i.v.) 0-12 mg/kg weekly x 4
PLM+MMC
PLM 25- mg (i.m.) twice daily (Days 1-5, and
15-19)
MMC (i.v.) 0 2 mg/kg weekly x 3
or PLM 0
-4 mg/kg (i.v.) weekly x 4
MMC (i.v.) 0 2 mg/kg weekly x 3
received bronchial arterial infusion of 8 mg
of carbazilquinone (CQ: alkylating agent)
5 weeks after the beginning of treatment, no
patient received any other systemic treat-
ment during this study.
Evaluation of treatment.-Baseline studies
of the extent of the disease before initiating
treatment consisted of chest roentgenogram,
lung tomogram, bone scan with roentgeno-
gram, liver scan, brain scan and minimal
laboratory studies, including complete blood
count, liver function, blood chemistry, and
urinalysis.
Follow-up every week included checking
the clinical status of the patient, and re-
cording symptoms, side effects of the drugs,
ECOG performance status (PS), and tumour
measurement in the chest roentgenogram.
Immunological tests for NK activity and
ADCC were also made every week.
At 6 weeks, the therapeutic response ofthe
primary tumour and metastatic lesions
(including pleural effusion) was evaluated.
The therapeutic responses were defined as
follows: complete response (CR), disappear-
ance of all symptoms and signs of disease
for at least 4 weeks; partial response (PR),
a decrease of ) 50% in the product of the
2 largest perpendicular diameters in all
measurable lesions, with no lesions develop-
ing for at least 4 weeks, or unequivocal
regression of evaluable but unmeasurable
lesions; stable disease (SD), <50% decrease
and <25% increase in the product of the 2
largestperpendiculardiameters ofallmeasure-
able lesions for at least 4 weeks; progressive
disease (PD) >25% increase in the size
ofany lesion, or appearance ofnew lesions.
Preparation of lymphocytes.-Peripheral
blood was obtained by venepuncture with a
needle attached to a plastic syringe contain-
ing heparin. The blood was diluted 1:1 with
Eagle's minimum essential medium (MEM),
and the mononuclear cells were separated
by centrifugation on a Ficoll-Conray cushion
(1080 g) according to Boyum's method
(Boyum, 1968). The interface was collected
and the cells were washed twice with MEM
and once with RPMI-1640 medium contain-
ing 10% heat-inactivated fetal calf serum
(RPMI-FCS). These mononuclear cells in
RPMI-FCS were incubated in a Falcon
3003 plastic dish (Falcon Plastics Co., U.S.A.)
in a humidified atmosphere of 5% C02,
95% air, at 37°C for 1 h. Later, nonadherent
cells were collected by repeated extensive
washing with MEM. More than 95% of
these nonadherent cells were lymphocytes,
which were used as effector cells for assaying
NK activity and ADCC. The number of cells
was adjusted (E/T ratio=50:1) before NK
and ADCC assay.
Tumour cells.-Two human cell lines,
K-562 derived from the pleural effusion of a
patient with chronic myelogenous leukemia
in blast crisis, and PC-9, derived from
adenocarcinoma of the lung (kindly donated
by Professor Y. Hayata, Tokyo Medical
College), were used as target cells in the
cytotoxicity assay.
Anti-PC-9 antibody.-The antibody used
for the ADCC assay was raised in an NZW
rabbit immunized by i.v. injection of PC-9
cells (3 x 107/3 ml) once a week for 5 weeks.
The pre-immune rabbit serum was used as a
control in the ADCC assay. The immune
and pre-immune sera were decomplemented
by heating at 56°C for 30 min, and absorbed
extensively with human type-AB RBC.
The absorbed sera were decomplemented
again before the experiments.
The appropriate dilution of immune serum
was between 1:100 and 1:1000 (Fig. 1).
Therefore, immune serum diluted 1: 256
was used for ADCC assay in all experiments.
The values for ADCC with the pre-immune
serum were almost the same as those for NK
activity (Fig. 1).
Labelling of tumour cells.-Target cells
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Cytotoxicity
Ii -
x x2 x 2 X2 x2 x2 x2
Dilution of serum
FIG. 1. --ADCC of lymphocytes fol PC-9
accor(ling to the dilution ofanti-PC-9 serum
(*) an(d preimmune serum ( ). Also slhowN-n
is NK acti-vity against PC-9 (0-9).
(2 5 x 106/(-25 ml) were incubated with 0-25
ml of 125 /Ci of Na251CrO4 (Japan Radio-
isotope Association, Tokyo) for 45 min, and
washed x 3 with 40 ml of RPMI-FCS to
remove unbound 51Cr. Finally, the cells
were suspended at a concentration of 105/ml
in RPMI-FCS. The amount of 51Cr released
spontaneously during incubation ofthe target
cells alone ranged from 10 to 20% of the
maximum.
Cytotoxicity assay. For the determination
ofNK activity, 0 lml quantities ofthe target-
cell suspension (105/ml) wNere mixed with
serial 2-fold dilutions of0 1 ml ofthe lympho-
cyte suspension (1 25-10 x 106/ml) wAhich
produced a final effector: target ratio of
125-100: 1. The reaction mixture w%Nere
carried out in the wells of96-well V-bottomed
inicrotitre plates (Limbro Scientific Co..
Hamden, Conn, U.S.A.). These plates were
incubated in a humidified atmosphere of
500 CO2, 95%o air at 37°C for 6 h.
For the determination of ADCC, 51Cr-
labelled PC-9 cells (104 in 0 05 ml of RPMI-
FCS) and 0 05 ml of anti-PC-9 antibody
(diluted 1:256 in RPMI-FCS) were incubated
in microtitre plates in a humidified atmo-
sphere of 500 C02, 950o air at 37°C for 1 h.
Effector cells in 0 1 ml (I 25-10 x 106/ml)
were added and incubation was continued for
6 h.
After incubation all the plates were
centrifuged at 400 g for 10 min, and 0P1 ml
of the supernatant from each well was
removed and its radioactivity was counted by
an auto-y-counter. Spontaneous target-cell
release was determined from the supernatant
of target cells cultured without effector
cells. The maximum releasable 51Cr was
Cytotoxicity (%o)
50 _ 0
25 - /
12.5 25:1 50 1 100
E/T ratio
FIG. 2.-NK activity for K-562 (00-*)
and PC-9 (0 ), an(l ADCC for PC-9
(0 - - -O) accor(ding to effector:target
ratio.
obtained by treatment with 5 cycles of
freezing and thawing in a dry-ice/alcohol
mixture and hot water. Triplicate cultures
were used throughout. The percentage of
cytotoxicity was calculated as:
Experimental release (ct/min)
100 x
-Spontaneous release (ct/min)
Maximum release (ct/mmn)
-Spontaneous release (ct/min)
ADCC= % cytotoxicity with anti-PC-9 anti-
body - 00 cytotoxicity with preim-
inune serum
The dose-response curve of NK activity
and ADCC in relation to E/T ratio is shown
in Fig. 2. Normal values of NK activity
against K-562, and NK activity and ADCC
against PC-9 were 43 0+3-1%O 8-7+15%0
and 43-7+±2*2%, respectively, at an E:T
ratio of 50:1. These values were obtained
from the average of 50 age-matched normal
volunteers. All NK data expressed in this
report are mean percentage release at an
effector:target ratio of 50: ], unless otherwise
indicated.
Statistical analysis.-All the data were
analysed by the 2-tailed t test to determine
the significance of differences between experi-
mental groups. P values were calculated by
comparing the experimental groups. Values
ofP < 0 05 w-ere considered significant.
RESULTS
Response to treatment and pretreatment
value of iNK activity and ADCC
No complete or partial responses were
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TABLE III.-Pretreatment level of NK activity aned ADC(
Target cell
NK K-562
ADCC PC-9
NK PC-9
Normal
43:0+±3 11
43 7+ 22
8 7+ 1 5
A gr'oup
41 1 + :3 9
49 5+3 1
7 2+0 8
Significance*
-N.S.
N.S.
N.S.
B gr'oup1)
27 4+7 1
30 4+4 5
4 2 + 0 4
Significancet
P<0 05
0< 002
P<001
* Between inormal andl A gr'oup (patienits with stabilized dlisease).
t Between normal an(l B group (patients with progressive (disease).
t Cytotoxicity (mean + s.e.).
Y.K.
CN A
T.N A Ai
(lecreased in Group A before treatment.
In contrast, in Group B these values were
significantly lower than normal, even
before treatment (Table III).
Changes in NYK activity and ADCC after
the initiation of chemiiotherapy
Pre"__ Fig. 3 shows the changes in NK activity
Pre i 2 3 4 5 6 and ADCC after the initiation of chemo-
s.YK therapy in 8 patients in Group A. NK
FS - activity against K-562, and NK activity
I - M.S. ^- t>-and ADCC against PC-9 cells were not
HA A decreased I week after the initiation of
TN. treatment. NK activity against K-562
and PC-9 tended to decrease 2 weeks
after the beginning of treatment, and
reached the lowest level at 3-4 weeks.
Pre 1 2 3 4 5 6 However, the activity was partially re-
e stored by 5 weeks, and returned to
Y.K. <>- pretreatment levels in 6 weeks, except
N, HA iMs t /ff for Patient Y.K., who received 8 mg of
sY. s <_\\ ghCQ by bronchial-artery infusion. The
T.N- \ = f i changes in ADCC after the initiation of
A */ chemotherapy were quite similar to those
,____,___,______________ ,___ of NK activity. All the patients were
Pre 1 2 3 4 5 6 dischargeable at the end of the chemo-
Weeks after the beginning of treatment therapy.
lChanges in NK activity and(l ADCC Fig. 4 shows the chainges in NK activity
the beginning of chemotherapy il and ADCC in 7 patients in Group B. All
p A patients (respon(lers). Y.K. was
inistered 8 mg of CQ 1y bronchilal- the activities began to decrease 2 weeks
y infusion at 5 weeks. after the initiation of treatment. NK
activity against PC-9 reached its lowest
level at this stage. NK activity against
d. Eight patients (Grouip A) ex- K-562 and ADCC against PC-9 reached
-d stabilized disease and 7 patients their lowest level at 3 and 5 weeks,
B) experienced progressive disease. respectively. None of the activities in this
oatients with pleural effusions were group of patients returned to normal
itrolled by tube drainage and local levels, even after 6 weeks, and none of
ion of anticancer agents. NK the patients in Group B could be dis-
against K-562, and ADCC and charged from hospital. All died within
tivitv against PC-9 were not 3 months of the initiation of treatment.
NK-activity
against
K-562(%)
50
ADCC
against
PC-9(%)
50
50
NK-activity
against
PC-9(%)
Fi. :3.-
after
groul
admi
arter,
observe
periencE
(Group
Three p
well cor
instillat
activity
NK ac
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NK-activity
against
K-562(%)
50
ADCC
against
PC-9(%)
50
T.K.
S.W.-
TFA
Pre 1 2
T.K.
KS.W.
Z.H. v
Pre 1 2
50 s-
S \.
NK-activity
against Z.H. PC-9(%) K
SNKA
S.W.
Pre 1 2
Weeks after the
FIG. 4.-Changes in NK actti
after the beginning of
in group B patients (progi
Detailed analysis ofNK activity and ADCC
in 6patients
Six patients who administered pepleo-
mycin (PLM) anticancer antibiotic, and
CQ were analysed for the effect of the
anticancer agents on NK activity and
ADCC. They were divided into 3 pairs
according to the route and timing of PLM
3 4 5 6 administration. Pair 1 received small
divided doses of PLM. Pairs 2 and 3
received large intermittent doses of PLM
simultaneously and alternately with CQ,
respectively.
Fig. 5 shows the changes in NK activity
< A- * and ADCC in the patients receiving small
divideddoses ofPLM, andCQ.PatientY.K.
6 received bronchial-artery infusion of 8 mg
3 4 5 6 of CQ 5 weeks after the initiation of treat-
ment. Response of these patients to treat-
ment was SD. In both cases, small divided
doses of PLM alone had no effect on NK
activity or ADCC. After the first dose of
6 mg CQ, NK activity against K-562 and
PC-9 began to decrease; in contrast,
ADCC against PC-9 did not change. One
3 4 5 6 week after the second dose of CQ, ADCC beginning of treatment
against PC-9 was significantly decreased
Lvityanl ADC and NK activity against K-562 and PC-9
chemothlerapy
ressive (itsease). reached the lowest level in both cases;
M.S.(Adenoca., T;N M ,PSI)
100
Cytotoxi city
(%)
501
100
.....
. . It . L ""' PLM 2.5mg, twice daily
I 4 CO 6mg, weekly
* Ak. \
Pre 1 2 3 4 5
PS (i) (1) (1) (2) (2) (1)
Weeks after the beginning of treatment
6 Pr.
(I) PS
Y.K.(Sq. cell ca., T.N2M,,PS3)
' ' . " " " '4 PLM 2.5mg, twice daily
Jr J J CO 6mg, weekly
t CO 8mg
I BAI
,e 2 3 4 S 6
S (3) ( 3) (3) (3) (2) (2) (2)
Weeks after the beginning of treatment
FIG. 5. Effect of chlemotlherapy on NK activity an(d ADCC in patients treated witlh small divide(d
(ose of pepleomycin (PLMI) whlose (lisease w-as stabilize(l. 0---0, NK (K-562); 0 0 CADCC
(PC-9); 0 0 NK (PC-9). PS, per-formanice status; BAI: bronchial artery infusion.
i
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C.N.(Sq. cell ca., T2NoMI, PSI-2), S.D.
100
It I J J PLM 20mg, weekly
J I J CO 6mg, weekly
S.S. (Large cell ca., T:;N2Mr,PS2), P.D.
I
J PLM 20mg, weekly
J CO 6mg,weekly
501
's~~ 0 -
Pre 1 2 3 4 5 6 Pre 1 2 3 4 5 6
PS (1-2) (1-2) (1-2) (1-2) (1-2 ) (1-2) (1-2) PS (2) (2) (2) (3) (3) (3) (4 )
Weeks after the beginning of treatment Weeks after the beginning of treatment
FIG. 6.-Effect of chemotherapy on NK activity and ADCC in patients treated with large inter-
mittent dose of pepleomycin simultaneous with CQ. 0 ---, NK (K-562); 0 O, AD)CC (PC-9);
0 0 NK (PC-9). PS, performance status.
these activities tended to be restored 5
weeks after the initiation of treatment.
In Patient M.S. they returned to pre-
treatment levels in 6 weeks. On the other
hand, these activities decreased again 1
week after the bronchial-artery infusion
of 8 mg CQ in Patient Y.K. These results
suggest that small divided doses of PLM
did not reduce NK activity and ADCC,
and that the two administrations of 6 mg
CQ weekly induced the marked decrease
in these activities; in addition, administra-
tion of CQ by the intra-arterial route had
the same effect as by the i.v. route.
Fig. 6 shows the changes in NK activity
and ADCC in patients receiving large
intermittent doses of PLM simultaneously
with CQ. In Patient C.N., whose response
100
Cytotoxicity
(0)
H.A.(Adenoca., T2N Mi,PS2), S.D. 100
Jr Ir Jr J PLM 20mg, weekly
CO 6mg, weekly
50 _
T.K. (Sq. cell ca., T,N2M),PS2), P.D.
It PLM 20mg, weekly
It CO 6mg, weekly
Pre 2 3 4 5i 6 Pre 2 3 4 5
PS (2) (2) (2) (2) (1-2) (1-2) (1-2) PS(2) (2) (2) (3) (3) (3)
Weeks after the beginning of treatment Weeks after the beginning of treatment
(3)
FIG. 7. Effect of chemotherapy on NK activity and ADCC in patients treated with large inter-
mittent dose of pepleomycin (alternating with CQ). 0- - -0* NK (K-562): 0C ADCC (PC-9):
0-0 NK (PC-9).
100
Cytotoxicity
(0)
50 _
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was SD, PLM and CQ were started
simultaneously, and 20 mg of PLM was
added in Week 4. On the otherhand, 20 mg
of PLM preceded the simultaneous com-
bination of PLM and CQ given 3 times in
Patient S.S., whose response was PD.
As shown in Fig. 6, NK activity and ADCC
decreased 1 week after the initiation of
treatment, stayed low through the 2nd
week, and showed slight recovery by the
3rd week in patient CN. In Patient S.S.,
20 mg ofi.v. PLM alone had no effect upon
NK activity or ADCC. After the beginning
of simultaneous administration of PLM
and CQ, the activities decreased, and did
not return to pretreatment levels.
Fig. 7 shows the changes in NK
activity and ADCC in patients receiving
large intermittent doses of PLM alter-
nately with CQ. The responses to treat-
ment were SD in H.A., and PD in T.K.
The changes in NK activity and ADCC
were essentially the same as in Fig. 6.
Again PLM alone did not affect either
activities, and the administration of CQ
apparently decreased both.
DIISCUSSION
In clinical practice, a number of tests
are conducted to determine the immune
reactivity of the patient (Hersh, 1981;
Sone et al., 1977). The principal cell in
immunological surveillance against cancer
has been thoughtto bethe T cell. However,
multiple immunological methods to evalu-
ate the T-cell functions have failed to
confirm a major role for the T cell in
immunological surveillance, since it is
difficult to demonstrate a good correlation
between the reactivity of the T cell and
the prognosis of the cancer. The role of
other potential antitumour effector cells
such as NK cells, K cells and macrophages
needs more intensive investigation
(McCredie et al., 1979; Saijo et al., 1980,
1 982a). NK cells have been shown to
lave cytotoxic activity against syngeneic,
allogeneic, and xenogeneic target cells
without prior sensitization. The character-
istics (including surface receptors) of
human NK cells have been investigated
intensively. On the other hand ADCC is
mediated by various leucocyte popula-
tions, depending on the target cell. When
nucleated target cells are used, ADCC is
mediated exclusively by a subpopulation
of lymphocytes known as killer or K cells.
The K cells have Fc receptors which inter-
act with specific immunoglobulins on the
surface of the target cell.
The in vivo significance of NK activity
and ADCC is still unclear, but these
activities seems consistent with the exist-
ence of a surveillance mechanism against
tumour growth (Menon & Stefani, 1978).
The potential role of NK activity and
ADCC in human cancer is now under
extensive investigation, in spite of the
inconsistent levels of NK activity and
ADCC in tumour-bearing patients (Eremin
et al., 1978; Forbes et al., 1981a, b;
McCredie et al., 1]979; Moore & Potter,
1980; Pross & Baines, 1976). In general,
anticancer agents are thought to suppress
NK activity and ADCC (Saijo et al.,
1982b). However, the kinetics of the
action of anticancer agents against NK
activity and ADCC are complicated.
MIantovani et al. (1978) reported that
azathiopurine and cyclophosphamide in-
duced an apparent decrease in NK
activity of mouse spleen lymphocytes 2
days after administration of the drug. On
the other hand, Santoni et al. (1980)
demonstrated an elevated NK activity in
peritoneal lymphocytes and a decrease in
spleen lymphocytes after the administra-
tion of Adriamycin. There are not enough
data about the effect of anticancer agents
on ADCC. McCredie et al. (1979) reported
that in patients with normal K-cell
activity surgery had no effect oni ADCC,
but in those with low values before surgery
there was a maximal decrease at 5 days,
with recovery by 15 days, and that radio-
therapy caused a marked decrease in
ADCC, maximal at 4 weeks, with recovery
by about 12 weeks in those who had no
known local or distant disease after the
completion oftreatment.
In this study, it was demonstrated that
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NK activity and ADCC in 7 patients with
poor prognosis were significantly decreased
even before treatment, and that they
began to decrease 2 weeks after the
initiation of treatment and reached the
lowest level at 3-4 weeks in all patients.
Thereafter, the activities returned to the
pretreatment level in 8 patients with
stabilized disease; in contrast, they were
not restored in 7 patients with progressive
disease and poor prognosis. These results
suggest that NK activity and ADCC are
valuable prognostic factors in patients
with Stage IIIMo and IIIM1 carcinoma of
the lung. In addition, we clearly demon-
strated that the effect of chemotherapy
on NK activity and ADCC differed
according to the drug used. Administra-
tion of CQ apparently decreased in NK
activity and ADCC, irrespective of the
route of administration. On the other
hand, the effect of PLM was not clearly
detected irrespective of timing, dose or
route of administration. It should be
stressed that the detailed analysis of the
effect of each anticancer agent on NK
activity and ADCC is necessary for the
establishment of better treatment regi-
mens for advanced carcinoma of the lung
(Saal et al., 1977). In spite ofthe promising
results of an attempt to monitor the
immune system in patients with Stage
IIIMo and IIIM1 carcinoma of the lung,
the phenomena observed in this pilot
study still await statistical confirmation
in a larger, controlled, more systematic
study. The complexities inherent in the
clinical situation and chemotherapeutic
regimens make it premature to engage in
detailed speculation about the precise
role played by the circulating cytolytic
lymphocytes. In addition, plastic non-
adherent cells were used as effector cells
of NK and ADCC assay throughout this
study. The composition of the lympho-
cyte population in the blood is an essential
factor for further assessment of the
significance of these data. Nevertheless,
we are encouraged by having a test
available which may give reproducible
information on chemotherapy induced
effects on immune reactivity and which
may correspond to the course of the
neoplastic disease.
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